Oxford University scientists are developing a new Ebola vaccine that could enter clinical trials within two to three months [1].
The development comes as the Democratic Republic of Congo faces a critical public health crisis in its eastern region. Because no proven vaccine currently exists for the Bundibugyo strain of the virus, this new candidate represents a vital medical option to contain the spread.
Professor Teresa Lambe of the Oxford Vaccine Group is leading the effort alongside other university researchers [1]. The team is utilizing the same viral-vector technology previously used to create the Oxford-AstraZeneca COVID-19 vaccine [2]. The goal is to produce a single-dose formulation to simplify administration in outbreak zones [2].
The urgency of the project is driven by the severity of the current situation in the DRC. This event is the third-largest Ebola outbreak on record [3]. The World Health Organization has raised its risk assessment for the region to "very high" [4].
The Bundibugyo strain is particularly lethal, with a mortality rate where around one-third of infected individuals die [2]. The lack of a targeted vaccine has left health officials with limited tools to stop the transmission of the virus in the eastern DRC.
Researchers are working to accelerate the timeline to ensure the vaccine can be deployed quickly. If the current trajectory holds, the transition to clinical trials will begin shortly to test the safety and efficacy of the single-dose approach [1].
“The vaccine could enter clinical trials within two to three months.”
The use of established COVID-19 viral-vector technology allows researchers to bypass the early stages of platform development, significantly shortening the window between discovery and clinical trials. By targeting the Bundibugyo strain specifically, Oxford is addressing a critical gap in global health security, as previous Ebola vaccines were not designed for this specific variant.
